DrugPatentWatch Database Preview
Chiesi Company Profile
» See Plans and Pricing
What is the competitive landscape for CHIESI, and what generic alternatives to CHIESI drugs are available?
CHIESI has twelve approved drugs.
There are twenty-two US patents protecting CHIESI drugs.
There are two hundred and sixty-two patent family members on CHIESI drugs in fifty countries and seventeen supplementary protection certificates in nine countries.
Summary for Chiesi
International Patents: | 262 |
US Patents: | 22 |
Tradenames: | 13 |
Ingredients: | 7 |
NDAs: | 12 |
Patent Litigation for Chiesi: | See patent lawsuits for Chiesi |
Drugs and US Patents for Chiesi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiesi | BRONCHITOL | mannitol | POWDER;INHALATION | 202049-001 | Oct 30, 2020 | RX | Yes | Yes | Start Trial | Start Trial | |||||
Chiesi | CARDENE | nicardipine hydrochloride | CAPSULE;ORAL | 019488-002 | Dec 21, 1988 | DISCN | No | No | Start Trial | Start Trial | |||||
Chiesi | CLEVIPREX | clevidipine | EMULSION;INTRAVENOUS | 022156-002 | Aug 1, 2008 | RX | Yes | Yes | 8,658,676 | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Chiesi
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chiesi | ZYFLO CR | zileuton | TABLET, EXTENDED RELEASE;ORAL | 022052-001 | May 30, 2007 | 5,422,123 | Start Trial |
Chiesi | CARDENE SR | nicardipine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020005-001 | Feb 21, 1992 | 3,985,758 | Start Trial |
Chiesi | ZYFLO | zileuton | TABLET;ORAL | 020471-003 | Dec 9, 1996 | 4,873,259 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CHIESI drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2016-01-29 |
➤ Subscribe | Injection | 2.5 mg/mL, 10 mL Ampoules | ➤ Subscribe | 2006-12-27 |
➤ Subscribe | Inhalation Solution | 300 mg/4 mL | ➤ Subscribe | 2017-08-31 |
➤ Subscribe | Injection | 0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL | ➤ Subscribe | 2013-06-20 |
International Patents for Chiesi Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Sweden | 9702680 | Start Trial |
Japan | 2018002739 | Start Trial |
Croatia | P20161443 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Chiesi Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0748228 | SPC/GB11/004 | United Kingdom | Start Trial | PRODUCT NAME: MANNITOL; REGISTERED: SE 22708 20061020; UK PL 27944/0001-0001 20071218 |
0726894 | SPC/GB12/011 | United Kingdom | Start Trial | PRODUCT NAME: CLEVIDIPINE; REGISTERED: UK PL16881/0003 20111123 |
1273292 | C01273292/01 | Switzerland | Start Trial | PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.